Business Context and Reporting Period
Company: Vyrex Corporation (Note: Metadata listed "374Water Inc." but filing text identifies "Vyrex Corporation")
Period: Quarter ended March 31, 2000
Status: Development stage enterprise focused on pharmaceutical and nutraceutical research.
Capital Structure: 7,792,867 shares of common stock outstanding; 1,156,701 warrants outstanding.
Key Financial Metrics
| Metric | Q1 2000 | Q1 1999 | Cumulative from Inception |
|---|---|---|---|
| Revenue | $9,983 | $22,416 | $399,273 |
| Net Loss | $(61,995) | $(315,724) | $(12,763,608) |
| EPS (Basic/Diluted) | $(0.01) | $(0.04) | $(1.96) |
| Cash & Equivalents (End) | $180,910 | $85,428 | $180,910 |
| Working Capital | $(156,992) | N/A | N/A |
| Total Liabilities | $497,902 | N/A | N/A |
| Accumulated Deficit | $(12,763,608) | N/A | $(12,763,608) |
Material Changes vs. Prior Period
- Revenue Decline: Royalty revenue dropped 55% to $9,983 from $22,416 due to a decline in sales of nutritional formulations following initial marketing in 1999.
- Expense Reduction: Operating expenses fell significantly. R&D expenses decreased by $145,000 and G&A by $133,000, primarily due to funding constraints that halted R&D work and reduced personnel.
- Net Loss Improvement: Net loss narrowed by approximately $254,000 to $62,000, driven by the reduction in operating costs.
- Capital Injection: Cash increased by $177,726 during the quarter, funded by $225,000 in private stock sales and a $15,000 bridge loan.
- Non-Cash Contribution: Three officers forgave $422,559 in accrued compensation, recorded as an addition to additional paid-in capital.
Outlook, Risks, and Management Commentary
- Going Concern Risk: Management explicitly states there is no assurance the company can continue as a going concern due to recurring losses, a net capital deficiency of $287,868, and negative working capital.
- Liquidity: Current cash reserves are projected to fund operations only through December 2000. The company has no bank lines of credit.
- Financing Needs: The company is actively seeking collaborative arrangements with pharmaceutical/nutraceutical partners or additional debt/equity financing. No commitments for future financing currently exist.
- Revenue Outlook: Management does not anticipate significant revenues in the foreseeable future without successful partnerships or product development.
- Recent Financing: A $15,000 bridge loan at 10% interest is due in February 2001. An additional $45,000 equity sale was committed in March but recorded in April 2000.
Investor Verification Checklist
- Verify the company's ability to secure additional financing before December 2000 to avoid insolvency.
- Confirm the status of negotiations with potential pharmaceutical or nutraceutical partners for licensing deals.
- Review the terms of the $15,000 bridge loan and any other related-party notes payable.
- Assess the impact of the $422,559 compensation forgiveness on future cash burn and management incentives.
- Validate the timeline for resuming R&D activities given the current halt in operations.